Single Drug Dependence And Heavy Financing Will Shape A Challenging Future

Catalysts

About Celcuity

Celcuity is a clinical stage biotechnology company focused on developing gedatolisib for hormone receptor positive, HER2 negative advanced breast cancer and metastatic castration resistant prostate cancer.

What are the underlying business or industry changes driving this perspective?

• Reliance on a single lead asset, gedatolisib, across multiple tumor types means any adverse regulatory outcome or weaker than expected real world effectiveness could reduce the value of the large estimated HR positive, HER2 negative breast cancer market and limit future revenue potential.
• Efforts to position gedatolisib as a new standard of care in second line breast cancer depend on broad oncologist adoption of triplet and doublet regimens targeting the PI3K/AKT/mTOR pathway, and slower adoption or preference for existing CDK4/6 based options could restrain uptake, pricing power and revenue ramp.
• Expansion into earlier lines of therapy and additional indications, including endocrine resistant first line and potential endocrine sensitive settings, requires large, long duration trials. Extended timelines or complex study designs could keep R&D expenses elevated relative to any future earnings for longer than investors expect.
• Plans to build a full commercial infrastructure in the US and engage ex US partners ahead of confirmed regulatory approvals imply a higher fixed cost base. If international approvals, reimbursement or partner deals progress more slowly than anticipated, net margins could be pressured even if US sales materialize.
• Heavy use of external financing, including US$287 million of convertible notes and equity plus a US$500 million term loan facility, increases future interest, dilution and repayment obligations. If cash burn remains near recent net loss and operating cash outflow levels, any revenue shortfall could weigh on earnings and constrain financial flexibility.

Assumptions

How have these above catalysts been quantified?

• This narrative explores a more pessimistic perspective on Celcuity compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
• Celcuity currently has no revenue. The bearish analysts are forecasting revenue to reach $414.4 million by March 2029.
• As a pre-revenue company, The bearish analysts expect Celcuity to achieve a profit margin of 31.3% in 3 years time.
• The bearish analysts expect earnings to reach $129.7 million (and earnings per share of $2.45) by about March 2029, up from -$162.7 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $358.8 million.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 50.6x on those 2029 earnings, up from -32.0x today. This future PE is greater than the current PE for the US Biotechs industry at 16.2x.
• The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.17%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• Gedatolisib has already produced positive Phase III data in the PIK3CA wild type cohort and is under real time oncology review. An eventual FDA approval in 2026 could give Celcuity a commercial product and undermine expectations of sustained losses, directly affecting future revenue and earnings.
• The VIKTORIA 1 results in second line HR positive, HER2 negative advanced breast cancer set new efficacy benchmarks for progression free survival and objective response rate. If oncologist adoption tracks the enthusiastic KOL feedback cited on the call, gedatolisib could gain meaningful share in a large treatment pool, which would support higher revenue than a bearish view assumes.
• Management is already running multiple late stage and earlier stage studies across breast and prostate cancer. If additional indications such as first line endocrine resistant disease or metastatic castration resistant prostate cancer read out positively, the long term addressable market could widen beyond current expectations, with potential upside to revenue and longer term earnings.
• Celcuity reports significant cash resources of about US$455 million plus access to a US$500 million term loan facility and expects funding through 2027. The current balance sheet and financing access reduce near term dilution or liquidity risk that could otherwise cap the share price, supporting the company’s ability to invest toward eventual positive net margins and earnings.
• Early payer and oncologist research, along with active ex US regulatory planning in Europe and Japan, point to potential future international partnerships and reimbursement. If these efforts translate into broader geographic uptake, that could add incremental revenue and scale benefits that improve net margins relative to a scenario where the drug remains primarily a US opportunity.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Celcuity is $94.0, which represents up to two standard deviations below the consensus price target of $120.9. This valuation is based on what can be assumed as the expectations of Celcuity's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $155.0, and the most bearish reporting a price target of just $94.0.
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $414.4 million, earnings will come to $129.7 million, and it would be trading on a PE ratio of 50.6x, assuming you use a discount rate of 7.2%.
• Given the current share price of $112.51, the analyst price target of $94.0 is 19.7% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.